Ms. Samira Sakhia reports

KNIGHT THERAPEUTICS ANNOUNCES LAUNCH OF WYNZORA® IN CANADA

Knight Therapeutics Inc. has launched Wynzora, a uniform white aqueous cream containing 0.05 milligram per gram of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada. Wynzora is indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12 and older.

"The launch of Wynzora in Canada reflects our commitment to continuing to grow our Canadian platform and bring innovative treatment options to patients. Wynzora's unique aqueous cream formulation, enabled by PAD Technology, offers patients and health care providers a clinically proven option that combines efficacy with ease of use, an important consideration for a chronic condition that requires long-term management," said Samira Sakhia, president and chief executive officer, Knight Therapeutics.

Knight obtained the Canadian rights to Wynzora through its June, 2025, acquisition of the assets of Paladin Pharma Inc. Paladin had entered into a licence agreement with MC2 Therapeutics Ltd. to commercialize Wynzora in Canada in November, 2024. MC2 is a private pharmaceutical company headquartered in Horsholm, Denmark, and in Guildford, U.K. Knight announced Health Canada approval of Wynzora in December, 2025.

About Wynzora

Wynzora is a cream-based fixed dose combination of CAL and BDP for topical treatment of psoriasis vulgaris developed by MC2. Wynzora has a broad mode of action by targeting keratinocyte proliferation and differentiation and inhibiting expression of pro-inflammatory hallmark cytokines such as IL-23, IL-17A/F and TNF-alpha. In Wynzora, the combination of CAL and BDP has greater anti-inflammatory and anti-proliferative effects than either component alone. Wynzora is uniquely enabled by MC2's formulation and drug delivery system PAD Technology, allowing an effective convenient-to-use aqueous cream formulation. Wynzora Cream was first approved in the United States by the Food and Drug Administration in July, 2020, followed by approvals in Europe in 2021, Australia in November, 2024, and Canada in December, 2025.

Wynzora is a registered trademark of MC2. All other trademarks are the property of their respective owners.

About psoriasis

Psoriasis is a chronic, immune-mediated inflammatory disease of the skin. It is often characterized by the presence of erythematous plaques, usually covered with silver, flaking scales. These plaques may be itchy or painful; depending on their extent and location, they may also be physically debilitating or socially isolating. An estimated one million Canadians and 125 million people worldwide are affected by psoriasis. Chronic plaque psoriasis (psoriasis vulgaris) is the most common type and accounts for 80 per cent to 90 per cent of cases. The severity of disease may vary among patients, ranging from mild to moderate to severe. The clinical course of psoriasis is unpredictable, with fluctuating severity over time.

Common symptoms of psoriasis include itching, redness, flaking and scaling. Itch is considered one of the most bothersome symptoms, with patients reporting itch reduction the most important treatment goal. Yet, the disease burden of psoriasis extends far beyond the physical dermatological symptoms. Psoriasis is considered a systemic inflammatory disorder, similar to rheumatoid arthritis, Crohn's disease and systemic lupus erythematosus.

About MC2 trials

The Health Canada approval was based on the results of two randomized, investigator-blind, vehicle-controlled eight-week phase 3 trials (MC2-01-C2 and MC2-01-C7) in adults, with CAL/BDP gel/suspension included as an active comparator. The trials were designed to show superiority of Wynzora to vehicle and non-inferiority to CAL/BDP (50 mcg/g CAL and 0.5 mg/g BDP) gel/suspension.

Results from both trials demonstrated that Wynzora had superior efficacy compared to vehicle (p less than 0.0001) for all confirmatory efficacy end points, including Physician Global Assessment (PGA) treatment success and mean percentage change from baseline in modified Psoriasis Area and Severity Index (mPASI) at week 8 In addition, Wynzora was non-inferior to CAL/BDP gel/suspension at week 8 for both PGA treatment success and mPASI.

The most frequently reported adverse reactions were application site reactions including irritation, pain, pruritus, eczema, exfoliation, telangiectasia and folliculitis, all occurring at a frequency below 1 per cent.

About MC2 Therapeutics

MC2 Therapeutics is a private dermatology innovation company developing science-based topical solutions, from prescription therapies to advanced dermo-cosmetics, leveraging its proprietary PAD Technology platform. Wynzora Cream, MC2's first PAD Technology-based commercial product, was launched in the United States in 2020 and is now approved in multiple regions, including Europe, Australia and Canada, through partnerships with leading pharmaceutical companies specializing in dermatology. MC2 Therapeutics is headquartered in Horsholm, Denmark, with additional R&D (research and development) and development operations in Guildford, United Kingdom.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing, and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.